Johnson & Johnson announced sales of $15 billion for the third quarter of 2010, a decrease of 0.7 percent from the third quarter of 2009, according to a company news release.
The company reported worldwide customer sales at $3.6 billion for the third quarter, a decrease of 10.6 percent from last year’s third quarter. Domestic sales decreased by 24.5 percent and international sales by 0.3 percent.
The company counted DePuy’s orthopedic joint reconstruction business among the contributors to the company’s operational growth, despite the recall of the ASR hip replacement. During this quarter, the company also filed a biologics license application in the U.S. to expand the SIMPONI label in rheumatoid arthritis to include inhibiting the progression of structural damage.
Read the release on Johnson & Johnson’s 3Q FY 2010 report.
Read other coverage on Johnson & Johnson: